(813) 971-8080

7210 Wareham Drive, Tampa, FL 33647

weight loss market

Eli Lilly Offers Weight Loss Drug Direct to Consumers

January 5, 2023 Eli Lilly and Company launched a website, lillydirect.com, to enable people to directly order from the drug maker including its weight-loss medicine Zepbound as well as connect people with obesity and other conditions with telehealth companies. The service, called LillyDirect, comes on the back on extraordinary demand seen over the last year

Eli Lilly Offers Weight Loss Drug Direct to Consumers Read More »

Medifast Enters Medical Weight Loss Market

Dec. 14, 2023 Medifast on Wednesday marked its first entry into the medically supported weight loss market through a collaboration with LifeMD Inc., a provider of virtual primary care. This venture brings together Optavia’s personalized, coach-guided approach with medical expertise from board-certified LifeMD clinicians and access to weight loss medications, including GLP-1s. Medifast has committed

Medifast Enters Medical Weight Loss Market Read More »

Medifast Reports Q3 Results

Nov. 7, 2023 Management stated: “Medically-supported weight loss solutions have brought a fresh focus to the landscape, and it’s important that we continue to develop an approach that recognizes the needs of the customers who choose to utilize medication as part of their health and wellness journey as we broaden our offerings, expand our addressable

Medifast Reports Q3 Results Read More »

Jenny Craig Relaunches – Now Delivering Meals Online

Sept. 27, 2023 Jenny Craig, a Wellful Inc., brand, has re-launched as a direct-to-consumer platform. The intermittent fasting focused, weight loss brand is now available for home delivery. In addition to home delivery service, consumers also may schedule appointments with weight loss coaches online.   In July, Wellful acquired Jenny at an undisclosed amount after the

Jenny Craig Relaunches – Now Delivering Meals Online Read More »

More Obesity Drugs in the Pipeline – Boehringer Ingelheim

August 20, 2023 Boehringer Ingelheim could soon stake a claim in the lucrative obesity treatment market after the pharma company said it has advanced a candidate into three Phase III trials following promising data. Servodutide, the company’s glucagon/glucagon-like peptide 1 (GLP-1) receptor dual agonist co-developed with Zeland Pharma, demonstrated up to 19% weight loss after

More Obesity Drugs in the Pipeline – Boehringer Ingelheim Read More »

Scroll to Top